Skip to main content

Table 1 Antidiarrhoeal effect of the crude extract of Matricaria chamomilla (Mc.Cr) against castor oil (10 mL/kg)-induced diarrhoea in mice without and with pre-administration of 3 mg/kg glibenclamide (GB) or 5 mg/kg 4-aminopyridine (4-AP)

From: Antidiarrhoeal, antisecretory and antispasmodic activities of Matricaria chamomilla are mediated predominantly through K+-channels activation

Group no.

Treatment

Dose (mg/kg)

Mean defecation/group

Mean no. of wet feces/group

Mean no. of dry feces/group

% Protection

1

Castor oil (10 mL/kg) + Saline

10

8.92 ± 1.24

7.81 ± 2.11

1.11 ± 0.21

12.4%

2

Castor oil + Cromakalim

10

6.67 ± 0.90#

2.32 ± 0.40###

4.35 ± 1.70#

65.2%

3

Castor oil + Loperamide

10

4.70 ± 0.90###

1.07 ± 0.30###

3.63 ± 0.90#

77.2%

4

Castor oil + Mc.Cr (p.o)

150

5.47 ± 1.37**

3.20 ± 0.50**

2.27 ± 0.58*

41.4%

5

Castor oil + Mc.Cr (p.o.)

300

4.20 ± 0.29***

1.61 ± 0.92***

2.59 ± 0.33*

61.7%

Effect of different treatments in the presence of GB or 4-AP

6

Castor oil + GB + Cromakalim

3 + 10

7.40 ± 0.95$

5.50 ± 0.70$$$

1.90 ± 0.85$$

25.6%

7

Castor oil + 4-AP + Cromakalim

5 + 10

6.70 ± 0.50

2.80 ± 0.75

3.90 ± 0.35$

58.2%

8

Castor oil + GB + Loperamide

3 + 10

4.90 ± 0.39

1.40 ± 0.50

3.50 ± 0.90

71.4%

9

Castor oil + 4-AP + Loperamide

5 + 10

5 ± 1.73

1.31 ± 0.90

3.69 ± 0.45

73.8%

10

Castor oil + GB + Mc.Cr

3 + 150

5.83 ± 0.50

3.84 ± 0.37$

1.99 ± 0.36

34.1%

11

Castor oil + 4-AP + Mc.Cr

5 + 150

6.11 ± 0.49$

4.73 ± 0.31$$

1.38 ± 0.41$

22.5%

12

Castor oil + GB + Mc.Cr

3 + 300

5.56 ± 0.50$

3.06 ± 0.57$$

2.50 ± 0.62

44.9%

13

Castor oil + 4-AP + Mc.Cr

5 + 300

5.80 ± 0.46$$

4.07 ± 0.57$$$

1.73 ± 0.70$

29.8%

  1. p.o. (per oral), Values shown are mean ± S.E.M. of 6 determinations.
  2. #p <0.05 and ###p <0.001 show a comparison of group #2 and 3 with group #1.
  3. *p <0.05, **p <0.01 and ***p <0.001show a comparison of group # 4 and 5 with group #1.
  4. $p <0.05, $$p <0.01 and $$$p <0.001 show a comparison of group # 6–13 with their respective treatments without GB or 4-AP (One-way ANOVA followed by Dunnet’s test).